Product Description: GDC-2394 is an orally active and selective NLRP3 inhibitor, and also inhibits IL-1β with IC50s of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β). GDC-2394 inhibits NLRP3-induced caspase-1 activity without inhibiting NLRC4-dependent inflammasome activation[1][2].
Applications: COVID-19-immunoregulation
Formula: C20H25N5O4S
References: [1]McBride C, et al. Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor. J Med Chem. 2022 Oct 24. /[2]Stafford, et al. Preparation of hexahydroindacenylcarbamoyldihydropyrazolooxazinesulfonamide derivatives and analogs for use as interleukin-1 activity inhibitors: World Intellectual Property Organization, WO2018136890[P]. 2018-07-26.
CAS Number: 2238822-07-4
Molecular Weight: 431.51
Compound Purity: 99.54
Research Area: Inflammation/Immunology
Solubility: DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Caspase;Interleukin Related;NOD-like Receptor (NLR)
English
Deutsch
